An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.
Lung Cancer (NSCLC)
DRUG: Tislelizumab Injection
ORR, Proportion of subjects with the best overall response (BOR), Up to approximately 2 years
DOR, DOR is the time between the first observed tumor responseto disease progression or relapse based on RECIST Version 1.1, Up to approximately 2 years|DCR, DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥8 weeks) based on RECIST Version 1.1, Up to approximately 2 years|PFS, PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first)., Up to approximately 2 years|OS, OS is the time from the date of randomization or first dosing date to death due to any cause., Up to approximately 2 years
This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.